Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indonesia Energy Corporation Limited (INDO) vs Eli Lilly And Co (LLY) Price & Performance

Indonesia Energy Corporation LimitedTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Indonesia Energy Corporation Limited vs Eli Lilly And Co — how do they compare? Indonesia Energy Corporation Limited trades at $2.85 (market cap $43.24M), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 24051.8× Indonesia Energy Corporation Limited's market cap, and Eli Lilly And Co pays a 0.59% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Eli Lilly And Co for 93 Days on average.

INDOLLY
Market Cap
$43.24M$1.04T
Volume
116,9533,064,878
Sector
EnergyHealth
52-Week High
$6.74$1.28K
52-Week Low
$2.49$799.57
Typical Hold Time
24 Days93 Days
Enterprise Value
$38.18M$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indonesia Energy Corporation Limited

INDO trades at $2.77 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $5.10 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.

Despite a 100% buy rating from analysts, fundamental weaknesses and negative earnings trends pose significant risks. The stock's outlook depends on successful execution of drilling operations to improve financial performance. Investors should weigh high operational risks against potential growth from new production.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.

Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INDO
100% Buy0% Sell
Avg holding period · 24 Days
LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Indonesia Energy Corporation Limited

Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.

Read more on INDO →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →